User profiles for Kiran Patel
Kiran PatelJanssen Verified email at its.jnj.com Cited by 30104 |
[HTML][HTML] Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
…, A Allred, D Ouellet, KB Kim, K Patel… - … England Journal of …, 2012 - Mass Medical Soc
Background Resistance to therapy with BRAF kinase inhibitors is associated with reactivation
of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we …
of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we …
[HTML][HTML] Improved survival with MEK inhibition in BRAF-mutated melanoma
…, FS Wu, D Ouellet, AM Martin, K Patel… - … England Journal of …, 2012 - Mass Medical Soc
Background Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are found
in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves …
in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves …
[HTML][HTML] Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
…, D Ouellet, AM Martin, N Le, K Patel… - … England Journal of …, 2014 - Mass Medical Soc
Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …
delays the emergence of resistance and reduces toxic effects in patients who have …
[HTML][HTML] Dupilumab in adults and adolescents with eosinophilic esophagitis
…, B Beazley, E McCann, K Patel… - … England Journal of …, 2022 - Mass Medical Soc
Background Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and
interleukin-13 signaling, which have key roles in eosinophilic esophagitis. Methods We conducted …
interleukin-13 signaling, which have key roles in eosinophilic esophagitis. Methods We conducted …
[PDF][PDF] Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with …
Purpose This phase III, randomized, double-blind, placebo-controlled study was conducted
to evaluate the efficacy and safety of sorafenib with carboplatin and paclitaxel (CP) in …
to evaluate the efficacy and safety of sorafenib with carboplatin and paclitaxel (CP) in …
Mars' surface radiation environment measured with the Mars Science Laboratory's Curiosity rover
The Radiation Assessment Detector (RAD) on the Mars Science Laboratory’s Curiosity rover
began making detailed measurements of the cosmic ray and energetic particle radiation …
began making detailed measurements of the cosmic ray and energetic particle radiation …
The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular …
…, E Lee, G Heatlie, F Leyva, K Patel… - Journal of the American …, 2009 - jacc.org
Objectives : The purpose of this study was to test the hypothesis that in heart failure with
normal ejection fraction (HFNEF) exercise limitation is due to combined systolic and diastolic …
normal ejection fraction (HFNEF) exercise limitation is due to combined systolic and diastolic …
[HTML][HTML] Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF …
…, Y Xu, DJ DeMarini, NT Le, K Patel… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Purpose BRAF mutations promote melanoma cell proliferation and survival primarily through
activation of MEK. The purpose of this study was to determine the response rate (RR) for …
activation of MEK. The purpose of this study was to determine the response rate (RR) for …
Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countries
…, A Wright, J Hsu, A Martiniuk, F Celletti, K Patel… - The Lancet, 2010 - thelancet.com
National health systems need strengthening if they are to meet the growing challenge of
chronic diseases in low-income and middle-income countries. By application of an accepted …
chronic diseases in low-income and middle-income countries. By application of an accepted …
[HTML][HTML] Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600–mutant colorectal cancer
… Messersmith, Adil Daud, Razelle Kurzrock, Mariaelena Pierobon, Shonda Little, Keith
Orford, Monica Motwani, Kiran Patel, Alan P. Venook, Scott Kopetz … Messersmith, Adil …
Orford, Monica Motwani, Kiran Patel, Alan P. Venook, Scott Kopetz … Messersmith, Adil …